Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Basit Öğe Kaydı
dc.authoridyasin, ayse irem/0000-0002-1528-8065
dc.authoridhacibekiroglu, ilhan/0000-0002-0333-7405
dc.authoridCAKIR, EMRE/0000-0003-0411-8818
dc.authoridFirat, Sedat Tarik/0000-0002-2358-8260
dc.authoridGoktas Aydin, Sabin/0000-0002-0077-6971
dc.authoridTekin, Omer/0000-0002-3920-4305
dc.contributor.authorYasin, Ayse Irem
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorSumbul, Bilge
dc.contributor.authorKoral, Lokman
dc.contributor.authorSimsek, Melih
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorOzturk, Akin
dc.date.accessioned2025-01-27T21:19:34Z
dc.date.available2025-01-27T21:19:34Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.
dc.description.sponsorshipOncological Clinical Research Association (ONKAD)
dc.description.sponsorshipThis study was funded by the Oncological Clinical Research Association (ONKAD). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.endpage1244
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue10
dc.identifier.pmid35081732
dc.identifier.scopus2-s2.0-85126490162
dc.identifier.scopusqualityQ2
dc.identifier.startpage1235
dc.identifier.urihttps://doi.org/10.2217/fon-2021-1248
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28666
dc.identifier.volume18
dc.identifier.wosWOS:000747186600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectcancer
dc.subjectchemotherapy
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectimmunotherapy
dc.subjectmalignancy
dc.subjectSARS-CoV-2
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu